Kvols Lk

733 citations
22 papers · 577 · h-index 10

Impact in

  • Oncology top 10%
    • Lung Cancer Research Studies
    • Pancreatic and Hepatic Oncology Research
  • Neurology top 5%
    • Neuroblastoma Research and Treatments

Papers in

Kvols Lk

21 papers receiving 527 citations

Peers

Kvols Lk
Comparison fields: 5 of 51
  • Oncology 327
  • Neurology 161
  • Epidemiology 328
  • Pulmonary and Respiratory Medicine 113
  • Hepatology 26
Replace R Bottomley with:
R Bottomley United States
P. J. Loehrer United States
Kazım Uygun Türkiye
B.G. Taal Netherlands
Bonnie J. Trochanowski United States
Toshiro Ogata Japan
Laura Tang United States
Peter Farha United States
Charlotte L. Maddock United States
M. Michael Australia
Kvols Lk relative to R Bottomley United States R Bottomley's profile →
Citations per field
00.5×5.0×
R Bottomley · 1×
Citations per year

Countries citing papers authored by Kvols Lk

Since Specialization
Citations

This map shows the geographic impact of Kvols Lk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kvols Lk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kvols Lk more than expected).

Fields of papers citing papers by Kvols Lk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kvols Lk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kvols Lk. The network helps show where Kvols Lk may publish in the future.

Co-authors

The 17 scholars most cited alongside Kvols Lk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kvols Lk Line = papers co-authored together Kvols Lk links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Cytoreductive hepatic surgery for neuroendocrine tumors.
1990294
2
Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
197779
3
VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
197842
4
High-resolution ultrasonographic and pathologic abnormalities of germ cell tumors in patients with clinically normal testes.
198326
5
The carcinoid syndrome: a treatable malignant disease.
198824
6
Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
197812
7
Phase II evaluation of AMSA in patients with metastatic lung cancer.
198011
8
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
198110
9
Evaluation of a fixed alternating treatment in patients with advanced breast cancer.
19789
10
A comparison of intra-arterial and cuff blood pressure measurements in very obese subjects.
19699
11
Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
19779
12
Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
19788
13
Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer.
19878
14
Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer.
19817
15
Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer.
19847
16
Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
19815
17
Phase II trial of iv 6-thioguanine in advanced colorectal carcinoma.
19815
18
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung.
19815
19
Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
19824
20
Molecular genetics of neuroendocrine tumors.
19932

About Kvols Lk

Kvols Lk is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Molecular Biology and Neurology, having authored 22 papers that have together received 577 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (8 papers), Neuroendocrine Tumor Research Advances (6 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (3 papers), Neuroblastoma Research and Treatments (3 papers), Head and Neck Cancer Studies (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Biochemical and Molecular Research (2 papers). The work is most often cited by research in Oncology (327 citations), Neurology (161 citations), Epidemiology (328 citations), Pulmonary and Respiratory Medicine (113 citations) and Hepatology (26 citations). Kvols Lk has collaborated with scholars based in United States. Frequent co-authors include Grant Cs, Moertel Cg, Stephen Frytak, Eagan Rt, Carr Dt, O'Connell Mj, Joseph Rubin, Horst Zincke, Edmonson Jh and Alexander Jk. Their work appears in journals such as PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact